Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07502716
NCT07502716AvailableNot Applicable

Compassionate Use of Ubamatamab

Regeneron Pharmaceuticals0 sitesStarted: March 31, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Available
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Provide Compassionate Use of Ubamatamab

Detailed Description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Study Design

Study Type
Expanded Access

Eligibility Criteria

Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Eligibility will be determined during the application review process.

Exclusion Criteria

  • Not provided

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials

Recruiting
Phase 1
Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
NCT07278856City of Hope Medical Center20
Recruiting
Phase 4
Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionUreteral Calculi
NCT07310797Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation500
Recruiting
Phase 2
Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.
NCT07392658Fondazione Ricerca Traslazionale33
Recruiting
Phase 2
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
NCT07290010Hebei Medical University Fourth Hospital25
Not yet recruiting
Not Applicable
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma
NCT07472621Henan Cancer Hospital20